Dysport vs Botox: Comparing the Two Leading Botulinum Toxin Brands

Few comparisons generate as much search interest, or as much confusion, as Dysport versus Botox. Both are built on the same active substance, yet clinics often develop a strong preference for one over the other. Understanding what genuinely differs between them — rather than assuming they are interchangeable or fundamentally opposed — is useful groundwork for any injector building a formulary.

The Shared Foundation

Botox and Dysport are both formulations of botulinum toxin type A, and share the same underlying mechanism: they interrupt the nerve signal that triggers muscle contraction, allowing the treated muscle to relax and the wrinkles it produces to soften. Botox is manufactured by Allergan and has been in clinical use for several decades; Dysport, produced by Ipsen, uses a different manufacturing process and excipient profile despite the shared active ingredient.

Shared Indications

In aesthetic practice, both products are used for broadly the same range of concerns:

• Crow's feet and periorbital lines
• Glabellar lines and forehead wrinkles
• Bunny lines across the nose
• Neck and chin wrinkles
• Facial asymmetry correction
• Hyperhidrosis (excessive sweating)
• Upper eyelid ptosis from tissue laxity

Where the Formulations Actually Differ

The practical differences between the two products lie in formulation and behaviour rather than mechanism:

• Diffusion characteristics. Dysport's molecular formulation is generally considered to spread more readily through surrounding tissue than Botox, which some practitioners favour for larger treatment areas such as the forehead, and others prefer to avoid near precise areas where diffusion could affect an adjacent muscle.
• Onset. Botox is often reported to show visible effect slightly earlier, around 72 hours post-treatment, while Dysport's effect is typically assessed from around two weeks.
• Duration. Both are generally described as lasting around three months, with some variation by individual metabolism and treatment area; effects may extend somewhat longer with consistent skincare and adherence to aftercare guidance.
• Dose units. Botox and Dysport are not measured on the same unit scale, so unit counts are not directly comparable between the two products — this is a formulation detail practitioners need to account for when working with either.

Choosing Between Them

Given the shared mechanism, the choice between Dysport and Botox in a given clinic often comes down to practitioner familiarity, patient history, and the specific treatment area, rather than one product being objectively superior. Some injectors keep both in their formulary and select based on area — for example, favouring one product's spread characteristics for a broad forehead treatment and the other for more contained areas such as the glabella. Supply reliability, product handling requirements and pricing are also practical factors in formulary decisions.

Vial size and packaging also differ between the two brands, which has practical implications for stock planning: a clinic offering both needs to account for different reconstitution volumes, storage requirements and shelf life once opened, and should plan procurement and appointment scheduling with those differences in mind rather than treating the two as directly interchangeable at the stock-room level.

Storage, Reconstitution and Handling

Both products are supplied as a freeze-dried powder requiring reconstitution before use, and both are sensitive to storage temperature and handling. Manufacturer guidance on reconstitution volume, storage conditions and shelf life after preparation differs slightly between the two brands, and following it closely is part of maintaining consistent potency — inconsistent handling is a more likely explanation for a disappointing result than any inherent difference between the products themselves.

Adverse Effect Profile

Reported adverse effects are broadly similar between the two products, given the shared active substance: transient injection-site bruising, redness or swelling, occasional headache, and, rarely, unintended effect on a nearby muscle if the product diffuses further than intended. Because Dysport's spread characteristics are generally considered wider than Botox's, some practitioners weigh this factor more heavily when treating areas close to the orbital rim or other zones where diffusion into an adjacent muscle would be more consequential.

A Note on Product Selection After a Poor Response

Where a patient has previously had an underwhelming result with one botulinum toxin brand, switching to a product with a different protein complex — Xeomin, for example, is manufactured without the accessory proteins present in Botox and Dysport — is sometimes considered, particularly if antibody-related resistance is suspected. This is worth exploring only after the more common explanations for an underwhelming result, such as assessment timing and technique, have been ruled out.

The Takeaway

Dysport and Botox share an active substance and a mechanism, but differ meaningfully in diffusion, onset and dosing units — differences that matter for formulary planning even though they rarely make one product a clear winner over the other. Familiarity with both broadens what a clinic can offer and gives more flexibility when a patient's history calls for a change.

For fine-gauge needles and injection consumables, see the needles and syringes range.